Brain injury is unpredictable in its consequences, affecting who we are, the way we think, act, and feel1. Identifying a brain injury early-on can impact treatment therapy and can improve patient outcomes. A partnership between Philips and Banyan Biomarkers of San Diego, is working to address this challenge.
Although active duty soldiers may sustain a traumatic brain injury (TBI), many others are afflicted while in garrison, or after retiring from the service. Cases of severe TBI are obvious and physically debilitating. However, mild TBI, or ‘mTBI’ (aka, concussion) can be more difficult to diagnose and its symptoms not immediately evident.
Those suffering from ‘post-concussion syndrome’ often struggle. Persistent symptoms adversely affect quality of life, spark behavioral changes and delay the patient’s ability to return to work/duty.
The question often asked is, how can we assess mTBI in its earliest stages to treat it more effectively? A simple blood test may be the answer.